A Phase II, Single-arm Study of Orally Administered BEZ235 as Second-line Therapy in Patients With Advanced or Metastatic Endometrial Carcinoma
Interventional
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
assess the efficacy of BEZ235 as measured by Overall Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST)
every 8 weeks
No
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
United States: Food and Drug Administration
CBEZ235C2201
NCT01290406
March 2012
December 2017
Name | Location |
---|---|
Henry Ford Hospital | Detroit, Michigan 48202 |
Texas Oncology, P.A. | Dallas, Texas 75246 |
University of Oklahoma Health Sciences Center | Oklahoma City, Oklahoma 73104 |
City of Hope Medical Center | Duarte, California 91010 |
Pacific Gynecology Specialists | Seattle, Washington 98104 |
Highlands Oncology Group | Springdale, Arkansas 72764 |
Cancer Care Northwest | Spokane, Washington 99202 |
University of Texas Southwestern Medical Center | Dallas, Texas |
Holy Cross Hospital | Silver Spring, Maryland 20910 |
Cancer Centers of North Carolina | Raleigh, North Carolina 27607 |
St. Joseph's Hospital & Medical Center | Phoenix, Arizona 85013 |
Morriswon Memorial Hospital | Morristown, New Jersey 07960 |
Carolinas Healthcare Systems | Charlotte, North Carolina 28203 |
GHS | Danville, Pennsylvania |
Sarah Gautam Rau | Nashville, Tennessee 37203-1197 |
STOH | San Antonio, Texas |